The study of LAENNEC (Human Placenta Hydrolysate) in patients with chronic liver diseases

illustrative image

The company Green Cross Wellbeing is enrolling patients into the clinical trial investigating Part A: in Patients With Chronic Liver Diseases, LAENNEC (Human Placenta Hydrolysate) is to Assess Safety and Tolerability After the Doses of Doses. Part B: Part A, it is to Determine the Optimal Dose by Evaluating Two Capacity and Placebo Groups.

The trial is designed to enroll male and female 19 Years to 74 Years and is being conducted in the Keimyung university dongsan medical center, Daegu, Korea, Republic of; Yeungnam university, Daegu, Korea, Republic of; Hanyang University Hospital, Seoul, Korea, Republic of; Korea university guro hospital, Seoul, Korea, Republic of; Severance hospital, Seoul, Korea, Republic of; Soonchunhyang university hospital, Seoul, Korea, Republic of; Wonju severance christian hospital, Wŏnju, Korea, Republic of.

The study start date is June 1, 2021. This page provides a more detailed overview of this clinical trial:

Clinical Research News

Upcoming Clinical Trials